Moderna Stock Price, News & Analysis

Moderna, Inc. (Nasdaq: MRNA) has supplied 30.4 million doses of its COVID-19 vaccine to the U.S. government, with 10.1 million administered in the country. The company is on track to deliver 100 million doses by the end of Q1 2021 and 200 million total by the end of Q2 2021. Moderna has increased its global production estimate for 2021 from 500 to 600 million doses, aiming for up to 1 billion doses. The vaccine has received Emergency Use Authorization from the FDA, and additional authorizations are pending in other countries.

Moderna, Inc. (Nasdaq: MRNA) announced a conference call on January 25 at 4:30 PM ET to discuss in vitro neutralization studies of its COVID-19 vaccine against emerging SARS-CoV-2 strains. The findings indicate that the vaccine retains neutralizing activity, a critical factor in ongoing pandemic response efforts. The call will also be accessible via a webcast. Over the past decade, Moderna has evolved significantly, demonstrating its mRNA technology's potential with multiple vaccines and therapies in development, enhancing its position in the biotechnology field.

Moderna (Nasdaq: MRNA) announced in vitro neutralization data for its COVID-19 Vaccine against emerging variants B.1.1.7 and B.1.351. The vaccine demonstrated strong neutralizing titers against B.1.1.7, with no significant decline. However, a six-fold reduction was observed against B.1.351, although levels remained protective. The company plans to conduct a Phase 1 trial for an emerging variant booster candidate, mRNA-1273.351. CEO Stéphane Bancel emphasized the importance of being proactive against evolving virus strains.

Moderna Inc (Nasdaq: MRNA) has initiated a Phase 1/2 clinical trial for its COVID-19 vaccine candidate (mRNA-1273 or TAK-919) in Japan, in partnership with Takeda Pharmaceutical Co. The study will involve 200 healthy adults and will assess the vaccine's safety and immunogenicity. Participants will receive two vaccinations 28 days apart. Pending licensure, Takeda plans to import and distribute 50 million doses starting in the first half of 2021. This represents Moderna's first clinical trial in Japan, aiming to enhance the country's COVID-19 vaccination efforts.

Moderna (Nasdaq: MRNA) and Uber (NYSE: UBER) have announced a partnership to enhance COVID-19 vaccine uptake. The collaboration will begin with providing vaccine safety information through Uber's app and will explore options like in-app ride scheduling for immunization appointments. Uber previously committed to offering 10 million free or discounted rides to facilitate access to vaccines, especially in underserved communities. Both companies aim to expand this initiative globally, reinforcing vaccine education and accessibility efforts.

Moderna (Nasdaq: MRNA) has appointed José M. Vega, M.D. as its new Chief Safety Officer as of January 11, 2021. Dr. Vega, who brings extensive experience from Merck and Amgen, will oversee safety and pharmacovigilance to ensure high standards of patient safety. His previous roles included leading a global team at Merck and holding significant positions at Amgen. This strategic hire is expected to support Moderna's growth and its commitment to delivering transformative mRNA medicines.

Moderna, Inc. (Nasdaq: MRNA) has received authorization from Swissmedic for its COVID-19 Vaccine in Switzerland. This milestone follows a rigorous examination of data from its Phase 3 clinical study. The Swiss Federal Government has ordered 7.5 million doses, with initial deliveries expected soon. Moderna's COVID-19 vaccine is already authorized in numerous countries, including the U.S. and EU, with ongoing applications under review globally. This approval marks a significant step in Moderna's efforts to combat the COVID-19 pandemic.

Moderna (Nasdaq: MRNA) is actively expanding its innovative vaccine pipeline following the success of its COVID-19 vaccine. The company has announced three new mRNA vaccine candidates targeting seasonal flu, HIV, and the Nipah virus. Additionally, it is broadening its respiratory syncytial virus (RSV) vaccine program to include older adults. CEO Stéphane Bancel highlighted the achievements of 2020 as a pivotal moment for Moderna, boosting confidence in pursuing more ambitious vaccine programs. With 24 mRNA candidates across five therapeutic areas, 13 are currently in clinical stages.

Moderna (Nasdaq: MRNA) received approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for its COVID-19 vaccine under Regulation 174. This temporary authorization is based on recommendations from the UK Commission on Human Medicines, allowing supply in Great Britain. The UK government has confirmed an additional purchase of 10 million doses, totaling 17 million doses. This marks the fifth jurisdiction to authorize the vaccine, and the first deliveries are expected early in 2021.